Post‐kala‐azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B
G Roustan, JA Jimenez… - British Journal of …, 1998 - academic.oup.com
Post‐kala‐azar dermal leishmaniasis (PKDL) is a rare clinical variant of cutaneous
leishmaniasis. It is very common in the Indian subcontinent and less frequent in East Africa …
leishmaniasis. It is very common in the Indian subcontinent and less frequent in East Africa …
Leishmania donovani Induced Cutaneous Leishmaniasis: An Insight into Atypical Clinical Variants in Sri Lanka
Y Siriwardana, B Deepachandi… - Journal of tropical …, 2019 - Wiley Online Library
Sri Lanka is a recent focus having Leishmania donovani induced cutaneous leishmaniasis
(CL) as the main clinical entity. A separate clinical entity within profile of CL was described in …
(CL) as the main clinical entity. A separate clinical entity within profile of CL was described in …
Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection
S Ajdary, MH Alimohammadian, MB Eslami… - Infection and …, 2000 - Am Soc Microbiol
Th1-type cellular immune responses play a critical role in protection against infection with
Leishmania parasites, whereas activation of Th2-type cells results in progressive disease …
Leishmania parasites, whereas activation of Th2-type cells results in progressive disease …
T-cell response in human leishmaniasis
A Kharazmi, K Kemp, A Ismail, S Gasim, A Gaafar… - Immunology letters, 1999 - Elsevier
In the present communication we provide evidence for the existence of a Th1/Th2 dichotomy
in the T-cell response to Leishmania antigens in human leishmaniasis. Our data suggest …
in the T-cell response to Leishmania antigens in human leishmaniasis. Our data suggest …
Characterization of the Local and Systemic Immune Responses in Patients with Cutaneous Leishmaniasis Due toLeishmania major
A Gaafar, B Veress, H Permin, A Kharazmi… - Clinical …, 1999 - Elsevier
In this study skin biopsies and peripheral blood samples were obtained from patients with
cutaneous leishmaniasis caused byLeishmania major. Samples were obtained at diagnosis …
cutaneous leishmaniasis caused byLeishmania major. Samples were obtained at diagnosis …
T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy
AM Da-Cruz, R Bittar, M Mattos… - Clinical and Vaccine …, 2002 - Am Soc Microbiol
ABSTRACT T-cell immune responses in patients with cutaneous leishmaniasis (CL) and
mucosal leishmaniasis (ML) were studied during the active disease, at the end of therapy …
mucosal leishmaniasis (ML) were studied during the active disease, at the end of therapy …
Post‐kala‐azar dermal leishmaniasis in visceral leishmaniasis‐endemic communities in Bihar, India
We assessed the prevalence of post‐kala‐azar dermal leishmaniasis (PKDL), a late
cutaneous manifestation of visceral leishmaniasis (VL), in 16 VL‐endemic communities in …
cutaneous manifestation of visceral leishmaniasis (VL), in 16 VL‐endemic communities in …
Leishmaniasis immunopathology—impact on design and use of vaccines, diagnostics and drugs
Leishmaniasis is a disease complex caused by 20 species of protozoan parasites belonging
to the genus Leishmania. In humans, it has two main clinical forms, visceral leishmaniasis …
to the genus Leishmania. In humans, it has two main clinical forms, visceral leishmaniasis …
Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood
Depressed cell-mediated immunity in human visceral leishmaniasis (VL)(also known as kala-
azar), revealed as the inability of peripheral blood mononuclear cells (PBMCs) to respond to …
azar), revealed as the inability of peripheral blood mononuclear cells (PBMCs) to respond to …